Results 41 to 50 of about 2,468 (182)

Reversal of Dabigatran Using Idarucizumab in a Septic Patient with Impaired Kidney Function in Real-Life Practice. [PDF]

, 2016
Background. Immediate reversal of anticoagulation is essential when facing severe bleeding or emergency surgery. Although idarucizumab is approved for the reversal of dabigatran in many countries, clinical experiences are lacking, particularly in special
Sauter, Thomas, Schlittler, Fabian, Blum, Sina, Ricklin, Meret, Nagler, Michael, Exadaktylos, Aristomenis   +5 more
core   +2 more sources

Successful thrombolytic therapy with recombinant tissue plasminogen activator in ischemic stroke after idarucizumab administration for reversal of dabigatran: a case report

Journal of Medical Case Reports, 2019
Background Idarucizumab is a specific antidote for the anticoagulant dabigatran. Although its efficacy has been recently reported, the drug is still in postmarketing surveillance and requires case data in different emergency settings. A newer intravenous
Toshiyuki Ohtani, Ryosuke Sintoku, Tasuku Yajima, Naoyuki Kaneko   +3 more
doaj   +1 more source

The (Fab)ulous Destiny of Idarucizumab: Highlighting Its Interference with Urine Protein Immunofixation

TH Open, 2019
Idarucizumab is a humanized antigen binding fragment (Fab) of a recombinant anti-dabigatran monoclonal antibody (IgG1-kappa) that allows rapid and sustained reversal of dabigatran-induced anticoagulation in case of bleeding or urgent surgery.
Nicolas Gendron, Héloïse Flament, Elena Litvinova, Sofia Ortuno, Nadine Ajzenberg, Dorothée Faille   +5 more
doaj   +1 more source

Two Dabigatran Fast Reversals in a 4-month Period – a Case Report

European Journal of Case Reports in Internal Medicine, 2019
Introduction: Idarucizumab is available for immediate reversal of dabigatran-induced anticoagulation in life-threatening bleeding or urgent surgery in patients with non-valvular atrial fibrillation (nvAF).
Vítor Fagundes, Mari Mesquita
doaj   +1 more source

Effective Removal of Dabigatran by Idarucizumab or Hemodialysis: A Physiologically Based Pharmacokinetic Modeling Analysis [PDF]

, 2020
Background Application of idarucizumab and hemodialysis are options to reverse the action of the oral anticoagulant dabigatran in emergency situations.
Lehr, Thorsten, Meibohm, Bernd, Fuhr, Laura Maria, Hanke, Nina   +3 more
core   +2 more sources

The Renal Elimination Pathways of the Dabigatran Reversal Agent Idarucizumab and its Impact on Dabigatran Elimination

, 2018
Idarucizumab, a humanized monoclonal antibody fragment (Fab), provides rapid and sustained reversal of dabigatran-mediated anticoagulation. Idarucizumab and dabigatran are mainly eliminated via the kidneys.
Markus Honickel, Joanne Van Ryn, Grottke, Oliver, Moschetti, Viktoria, Reilly, Paul, Honickel, Markus, Guanfa Gan, Gan, Guanfa, Viktoria Moschetti, Stephan Glund, Oliver Grottke, Glund, Stephan, Paul Reilly, van Ryn, Joanne   +13 more
core   +1 more source

Lack of Differences in the Pharmacokinetics of Therapeutic Monoclonal Antibodies Between Japanese and Non‐Japanese Individuals

The Journal of Clinical Pharmacology, Volume 66, Issue 8, August 2026.
Abstract Evaluation of the pharmacokinetics (PK) of new drugs in Japanese individuals is regularly requested by the Japanese regulatory agency prior to participation in global clinical trials or for bridging approaches for regulatory approval. However, the need for PK assessments in the Japanese population may be less compelling for monoclonal ...
Paridhi Gupta, Ashish Sharma, Bernd Meibohm   +2 more
wiley   +1 more source

Intravenous Thrombolysis After Reversal of Dabigatran With Idarucizumab in Acute Ischemic Stroke: A Case Report

Frontiers in Aging Neuroscience, 2021
Background: As there is a growing concern about the cerebral embolism events secondary to non-valvular atrial fibrillation (NVAF), novel oral anticoagulant (NOAC) has been more and more widely used as an anticoagulation treatment for the prevention of ...
Dan Xie, Xuefan Wang, Yao Li, Ruiling Chen, Yingying Zhao, Chunling Xu, Qian Zhang, Yongbo Zhang   +7 more
doaj   +1 more source

Consensus Guides on Stroke Thrombolysis for Anticoagulated Patients from Japan: Application to Other Populations [PDF]

Journal of Stroke, 2018
Development of direct oral anticoagulants and their antidotes has led to the need to reconsider the eligibility of acute stroke patients who have been taking oral anticoagulants for intravenous thrombolysis.
Kazunori Toyoda, Hiroshi Yamagami, Masatoshi Koga   +2 more
doaj   +1 more source

Consensus Recommendations for Clinical Pharmacist Integration into the Acute Stroke Care Team: Endorsed by the American College of Clinical Pharmacy, Neurocritical Care Society, Society for Academic Emergency Medicine, and Society of Critical Care Medicine, and affirmed by the American Academy of Neurology

JACCP: JOURNAL OF THE AMERICAN COLLEGE OF CLINICAL PHARMACY, Volume 9, Issue 7, July 2026.
Graphical abstract of consensus recommendations for clinical pharmacist integration into the acute stroke care team. ABSTRACT Clinical pharmacists are increasingly recognized as vital contributors to acute stroke care, yet their role remains inconsistently defined and underutilized across health care systems.
Brian W. Gilbert, Caitlin S. Brown, Nicole M. Acquisto, Kellyn K. Engstrom, Kevin J. Mercer, Gavin T. Howington, David E. Zimmerman, Michael Gottlieb, Alicia E. Mattson, Megan A. Rech, Erin D. Wieruszewski, Andrew J. Webb, Brett Faine, Lance C. Ray, Kent A. Owusu, Barbara Voetsch, Dana Gerberi, Kristin Cole, Fernanda Bellolio   +18 more
wiley   +1 more source